Acute myeloid leukaemia
A fast-growing cancer of the blood and bone marrow, in which the marrow makes large numbers of abnormal, immature white blood cells. It can cause tiredness, pale skin, shortness of breath, easy bleeding or bruising, and getting ill a lot. Treatment needs to start quickly and is mainly chemotherapy, sometimes with targeted medicines or a stem cell transplant. It can happen at any age, but it is more likely after 60, and the risk keeps rising with age.
Read more about acute myeloid leukaemiaTrial-stage treatments and research studies you can join
Filters
- Testing Venetoclax Plus Azacitidine With or Without Gilteritinib for FLT3 Leukemia
Tests adding gilteritinib to venetoclax and azacitidine in older adults with FLT3-mutated leukemia.
Montreal, CanadaAge 18+ - Tests ziftomenib with standard drugs for untreated AML with certain gene changes
Tests ziftomenib with standard drugs in adults with new AML and certain genes.
Montreal, CanadaAlso VancouverAge 18+ - Testing New Treatment Combinations for Newly Diagnosed High-Risk Acute Myeloid Leukemia
Compares newer drug combinations with standard chemotherapy in adults with high-risk acute myeloid leukemia.
Calgary, CanadaAlso Edmonton, Greenfield Park, Halifax, Montreal, Ottawa, Toronto, WinnipegAge 18 to 59 - Tests bleximenib with venetoclax and azacitidine for newly diagnosed acute myeloid leukemia
Tests bleximenib with venetoclax and azacitidine in adults newly diagnosed with acute myeloid leukemia.
Calgary, CanadaAlso Halifax, Hamilton, London, Montreal, Toronto, Vancouver, WinnipegAge 18+ - Testing venetoclax added to chemotherapy in younger adults with intermediate risk acute myeloid leukemia
Compares chemotherapy, chemotherapy plus venetoclax, and venetoclax plus azacitidine in younger adults with leukemia.
Calgary, CanadaAlso Edmonton, Greenfield Park, Halifax, Hamilton, Montreal, Toronto, WinnipegAge 18 to 59 - Tests AZD3632 alone or with other drugs in advanced blood cancers
Tests the oral drug AZD3632 in adults with advanced leukemia or myelodysplastic syndromes.
Montreal, CanadaAlso TorontoAge 16+ - Tests revumenib with chemotherapy for newly diagnosed acute myeloid leukemia with NPM1 mutation
Tests revumenib added to chemotherapy in people aged 12 and older with newly diagnosed AML.
London, CanadaAlso Montreal, TorontoAge 12+ - Tests revumenib in people with relapsed or hard-to-treat acute leukemia
Tests revumenib in adults and children with acute leukemia that returned or did not respond.
Toronto, CanadaAge 0+ - Tests ziftomenib with chemotherapy in children with relapsed acute leukemia
Tests ziftomenib with chemotherapy in children whose acute leukemia returned or did not respond.
Toronto, CanadaAge 0 to 21 - Tests oral ASTX030 alone or with venetoclax in myeloid blood cancers
Tests an oral form of azacitidine, alone or with venetoclax, in adults with blood cancers.
St. John's, CanadaAlso TorontoAge 18+ - Adding Gilteritinib to Azacitidine and Venetoclax for Relapsed or Resistant Acute Myeloid Leukemia
Tests adding gilteritinib to standard treatment in adults with returned or unresponsive acute myeloid leukemia.
Vancouver, CanadaAge 18+ - Compares standard chemotherapy with CPX-351 and gilteritinib in newly diagnosed leukemia
Tests CPX-351 and gilteritinib with chemotherapy in children and young adults with leukemia.
Calgary, CanadaAlso Edmonton, Halifax, Hamilton, Kingston, London, Montreal, Ottawa, Québec, …Age 0 to 21 - Tests bezuclastinib in adults with advanced systemic mastocytosis
Tests bezuclastinib in adults with advanced systemic mastocytosis, a rare blood disease.
Edmonton, CanadaAlso TorontoAge 18+ - Continued ASTX727 treatment for people from earlier studies with blood cancers
Gives continued ASTX727 to adults with blood cancers who benefited from earlier studies.
Edmonton, CanadaAlso Ottawa, TorontoAge 18+ - Levofloxacin to Prevent Infections in Outpatients With Myelodysplastic Syndromes or Acute Myeloid Leukemia
Tests levofloxacin against usual care to prevent infection in adults with these blood cancers.
Winnipeg, CanadaAge 18+ - Tranexamic Acid to Prevent Bleeding in Myelodysplastic Syndromes and Leukemia
Tests tranexamic acid against placebo to prevent bleeding in adults with blood cancers.
Winnipeg, CanadaAge 18+ - ThINKK Immune Cell Therapy After Stem Cell Transplant in Children With Leukemia or Neuroblastoma
Tests ThINKK immune therapy in children after transplant for leukemia or neuroblastoma.
Montreal, CanadaAlso TorontoAge 2 to 12 - Tests enzomenib in people with acute leukemia or related blood cancers
Tests enzomenib, a new drug, in people 12 and older with acute leukemia.
Calgary, CanadaAlso EdmontonAge 12+ - Tests HQP1351 pill in adults with resistant chronic myeloid or Ph+ leukemia
Tests the oral drug HQP1351 in adults with leukemia that stopped responding to earlier treatments.
Toronto, CanadaAge 18+ - Blood and marrow marker tests in acute myeloid leukemia and myelodysplastic syndrome
Tests blood and marrow markers in people with myeloid cancer.
Calgary, CanadaAlso Edmonton, Greenfield Park, Halifax, Hamilton, Montreal, Ottawa, Toronto, WinnipegAge 18+
Trials that have ended are not listed here, because nobody can join them. Stopped and finished Acute myeloid leukaemia trials (research view)
Where treatment stands
Approved: 34
Officially approved for this disease in the EU, the US, Switzerland or France.
Human testing stage: 32
Being tested in people. Many treatments at this stage are never approved.
Animal testing stage: 5
Worked in animals in a study published in the last 12 months. Most treatments at this stage never reach people.
Lab research stage: 2
Worked on cells in the lab in a study published in the last 12 months. Most early ideas never reach people.
Placebo: a dummy treatment without the medicine, used for comparison.
Phase 1, 2, 3: the steps of testing in people. Phase 1 checks safety, phase 3 is the last step before approval.
The EU medicines agency (EMA) and its list of medicines in the EU, US prescribing labels (DailyMed, openFDA), the Swiss medicines register (Swissmedic), the French medicines database (ANSM) and the Health Canada drug database, checked on 11 November 2026. Every medicine links to its own official text.
A computer made this list from the official texts: it kept only medicines whose own approval text names the disease, wrote "Who it is for" from that text and checked it against the text a second time. People have not reviewed it yet.
The EU medicines agency (EMA), ClinicalTrials.gov and the EU trials register, checked on 10 November 2026. Every treatment links to its own records; the texts are written by AI from them.
Medicines approved only in single countries are not included. We did not check in which countries a medicine is sold or paid for. Phase 3 trials are listed from every country; only some phase 2 trials are listed, so 209 other open phase 2 trials are not listed.
Animal and lab research: studies listed in PubMed and published in the 12 months before 12 November 2026, found by a search for acute myeloid leukaemia. AI chose the treatments from the study summaries and wrote the texts; a second AI checked each one against its study summary. People have not reviewed them yet. Treatments already in the approved or human testing lists are left out. A result in animals or cells does not show that a treatment works in people.
Not medical advice. Talk to your doctor before you change any treatment.
The approval records under a medicine come from Drugs@FDA and the FDA labels (openFDA) and from the EU medicines agency’s medicine data, with its orphan designations, checked on 13 Nov 2026. A date is the medicine’s first approval, for any use; the quoted text is its approved use as written today.
Support organisations
Patient organisations and helplines in Canada, for you and your family.
Acute myeloid leukaemia organisations in Canada
- Canadian Cancer Society
Canada's largest national cancer charity, funding cancer research, offering cancer information and support services and advocating for public policy.
- Fondation québécoise du cancer
Quebec foundation supporting people with cancer and their families during treatment with information and daily support services.
General support in Canada
- 9-8-8: Suicide Crisis Helpline
National 24/7 suicide crisis helpline: call or text 9-8-8 to connect with a trained crisis responder without judgement.
- Kids Help Phone
National 24/7 e-mental health service for young people: call, text or chat for free, confidential support.
International organisations
- DKMS
Finds blood stem cell donors worldwide so that people with blood cancer can have a transplant.
Offer tissue or data
There are three ways to help research move faster.
Approved treatments
32 medicines are approved for acute myeloid leukaemia in at least one of the places we checked. An approval in one place does not mean the medicine is offered or paid for where you live.
Checked on 11 Nov 2026 in the official lists of the US (FDA), the EU (EMA), Japan (PMDA, approvals since April 2004), Switzerland (Swissmedic), France (ANSM, medicines approved in France only) and Taiwan (TFDA). For Canada (Health Canada) and Singapore (HSA) we checked only whether a medicine is sold there, not what for. 6 uncertain matches are left out. Other countries' own approvals were not checked.
“Miracle cure” fact checker
Social media spreads misinformation. Paste here what you read, and we'll tell you whether there is scientific evidence behind it.
What you paste is checked with AI (Anthropic, USA) and is not stored. Please leave out names and other personal details.
Before you pay for anything, ask three things
- Is there a published study in people?
- Can I have the full price in writing?
- What does my doctor say?
“Cures” others already fact-checked
- Ivermectin & Acute myeloid leukaemia
- Fenbendazole & Acute myeloid leukaemia
- CBD (cannabidiol) & Acute myeloid leukaemia
- Vitamin C (incl. high-dose) & Acute myeloid leukaemia
About acute myeloid leukaemia
Sources: NHS, NCI PDQ, Cancer Research UK, The New England Journal of Medicine
A fast-growing cancer of the blood and bone marrow, in which the marrow makes large numbers of abnormal, immature white blood cells. It can cause tiredness, pale skin, shortness of breath, easy bleeding or bruising, and getting ill a lot. Treatment needs to start quickly and is mainly chemotherapy, sometimes with targeted medicines or a stem cell transplant. It can happen at any age, but it is more likely after 60, and the risk keeps rising with age.
What is it?
AML is a rare cancer of the blood and bone marrow. Bone marrow, found in the centre of most bones, makes blood cells. In AML it makes large numbers of abnormal, immature white blood cells that crowd out the healthy ones. It is the most common type of acute leukaemia in adults. 'Acute' means it gets worse quickly, so treatment needs to start fast.
It can happen at any age, but it is more likely after 60. Being male may also raise the risk. The risk is also higher if you smoke, had chemotherapy or radiotherapy in the past, have another blood disorder, have a genetic condition such as Down's syndrome, or were often exposed to high levels of the chemical benzene. It is not always clear what causes it.
The first signs
The signs are often not obvious at first and can feel like flu. They usually come on quickly, over a few weeks:
- feeling very tired or weak;
- looking paler than usual (on brown or black skin, check the palms or the inside of the eyelids);
- getting out of breath;
- bleeding or bruising easily;
- a high temperature, or getting ill a lot or taking longer than usual to recover from illnesses;
- aching bones or joints, a swollen tummy or swollen glands.
They can be caused by many other conditions, but they need checking.
How doctors find out
Your family doctor usually arranges an urgent blood test, and may send you to a hospital specialist or straight to hospital. The main tests are blood tests and a bone marrow biopsy: a small sample of marrow is taken with a needle from the hip bone or breastbone, usually after numbing the skin. Gene tests on the leukaemia cells help choose the treatment. You may also need a lumbar puncture (a little fluid taken from the lower back) and scans. Blood results can come within a few days; other tests take a few weeks.
Current treatment
Intensive chemo, sometimes a stem cell transplant
Will it get worse?
Without treatment, AML gets worse quickly, but it is often treatable. How serious it is depends on the type of AML, your age and your general health. In older people, the leukaemia may be less likely to go into remission. Even after remission, the leukaemia can come back, which is why treatment carries on afterwards. When AML cannot be cured, treatment aims to control it, ease symptoms and help you live longer.
Medicines: what helps, and what to watch for
Chemotherapy is the main treatment, usually several medicines together. Intensive treatment aims to cure the leukaemia and is usually given in hospital. Non-intensive treatment aims to control it for as long as possible; it is usually given at home and has fewer side effects. Targeted medicines can be added, for example when the leukaemia has a change in the FLT3 gene. One type, acute promyelocytic leukaemia, may be treated with ATRA and arsenic trioxide.
Good to know:
- Treatment comes in phases: first to clear the leukaemia from the blood and marrow, then more treatment to kill any cells that are left;
- AML and chemotherapy lower your blood counts, so you are watched closely and may need blood and platelet transfusions;
- You may get antibiotics and antifungal medicines to prevent or treat infections;
- You have regular check-ups, tests and scans during and after treatment;
Exercise and diet help too
Tiredness is one of the most common problems and can continue for months after treatment. After treatment, exercise can help your body and your mood: start gently, for example with walking, and build up slowly. You can go swimming once your white blood cell count is back to normal and you no longer have a central line. A good, balanced diet might help you feel stronger and recover more quickly. Your nurse can refer you to a dietitian or a physiotherapist.
- After a stem cell transplant, your team may give you food-safety advice for the first few months, such as eating only freshly cooked food;
A transplant, for some people
A stem cell or bone marrow transplant replaces the damaged blood-making cells with healthy ones. First you get high-dose chemotherapy, sometimes with radiotherapy, and then the stem cells are given back to you through an infusion. They can be your own cells or come from a donor. It may be offered if the leukaemia is likely to come back, has come back, or other treatments are not working.
Is there a cure?
Sometimes. Intensive treatment aims to cure AML, and more than 1 in 4 adults live 3 years or more and may be cured. For others, treatment aims to keep it under control. New treatments are being tested in clinical trials.
Median survival
About 15 months with azacitidine and venetoclax, for people who cannot have intensive chemotherapy
Measured in: Previously untreated AML in people who could not have intensive chemotherapy (median age 76): the VIALE-A trial (431 patients)
The figures behind it
VIALE-A (431 previously untreated patients who were ineligible for intensive chemotherapy, median age 76): median overall survival 14.7 months with azacitidine plus venetoclax vs 9.6 months with azacitidine alone. People who can have intensive chemotherapy are not part of this figure.
Sources
Written in plain words by Frontlight from these pages:
- NCI PDQ: Acute Myeloid Leukemia Treatment (PDQ®) – Patient Version
- NHS: Acute myeloid leukaemia – Symptoms
- NHS: Acute myeloid leukaemia – Treatment
- NHS: Acute myeloid leukaemia – What is AML?
- NHS: Acute myeloid leukaemia – Causes
- NHS: Acute myeloid leukaemia – Tests and next steps
- Cancer Research UK (charity): Coping with acute myeloid leukaemia
- Cancer Research UK (charity): Diet and physical activity after AML
- NCI PDQ: Adult Acute Myeloid Leukemia Treatment (PDQ®) – Health Professional Version
- The New England Journal of Medicine: Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia